form8-ka.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K/A
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): September 18,
2007
SANGUI
BIOTECH INTERNATIONAL, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Colorado
(State
or
Other Jurisdiction of Incorporation)
000-21271
84-1330732
(Commission
File
Number) (IRS
Employer Identification No.)
Alfred-Herrhausen-Str.
44, 58455 Witten, Germany
(Address
of Principal Executive Offices) (Zip Code)
011-49-2302-915-204
(Registrant's
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
Item
4.01. Changes in Registrant’s Certifying Accountant.
(a)
On
September 18, 2007, the Board of Directors of Sangui Biotech International,
Inc.
(“Company”) dismissed HJ & Associates, LLC (“HJ & Associates”) as the
Company's independent auditors.
HJ
&
Associates audited report of the financial statements for the years ended June
30, 2005 and 2004, included language expressing substantial doubt as to the
Company's ability to continue as a going concern. The audit report
contained no other adverse opinion or disclaimer of opinion and was not
qualified or modified as to uncertainty, audit scope or accounting
principles. As such, in connection with these audits of the
fiscal years ended June 30, 2005 and 2004 and the subsequent interim period
prior to such dismissal, there were (1) no disagreements with HJ &
Associates on any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure, which disagreements,
if
not resolved to the satisfaction of HJ & Associates, would have caused them
to make reference thereto in their reports on the financial statements for
such
periods to the subject matter of the disagreement, and (2) there were no
reportable events as that term is defined in Item 304(a)(1)(iv) of Regulation
S-B. The change in independent accountants did not result from any
dissatisfaction with the quality of professional services rendered by HJ &
Associates.
The
Company has provided HJ & Associates with a copy of the foregoing
disclosure, and has requested that HJ & Associates furnish it with a letter
addressed to the Securities and Exchange Commission stating whether or not
it
agrees with such disclosure. The Company has filed, as Exhibit 16.1 to this
Form
8-K, a copy of the letter from HJ & Associates as required by Item 304(a)(3)
of Regulation S-B.
(b)
On September 18,
2007, the Company engaged of the accounting firm of Moore & Associates,
Chartered ("Moore & Associates") as its independent auditors, effective
immediately. Moore & Associates have
been
asked to audit the Company's financial statements for the years ending June
30, 2006 and 2007. During the two most recent fiscal years and the
subsequent interim periods prior to the engagement of Moore & Associates,
the Company did not consult with Moore & Associates with regard to: (i) the
application of accounting principles to a specific completed or contemplated
transaction, or the type of audit opinion that might be rendered on the
Company's financial statements; and further, Moore & Associates have not
provided written or oral advice to the Compnay that was an important factor
considered by the Company in reaching a decision as to any accounting, auditing
or financial reporting issue; or (ii) any matter that was either the subject
of
a disagreement or a reportable event (as described in Item 304(a)(1)(iv) of
Regulation S-B).
The
decision
to change principal auditors and the engagement of the new principal auditor
was
recommended and approved by the Company's Board of
Directors.
Item
8.01 Press Release
On
September
21, 2007, the Company issued a Press Release announcing the change in Auditors.
A copy of the release is included as exhibit 99.1 to this Report on Form
8-K.
Item
9.01. Financial Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
|
16.1
|
|
Letter
re Change in Certifying Accountant
|
| |
|
|
99.1
|
|
Press
Release
|
SIGNATURES
Pursuant
to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report
to
be signed on its behalf by the undersigned hereunto duly
authorized.
Sangui
Biotech International,
Inc.
Date: October
5, 2007
/s/ Wolfgang Barnikol
_______________________________________
By:
Wolfgang Barnikol
Its: President,
CEO and CFO